Physician profile
Daniel Robins
NPI 1336352699
$12,495.40
in general payments reported to CMS, 2019-2025
43 companies · $1,979 in 2025
The $1,979 reported for 2025 was more than what 76% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,550 · 2020: $1,554 · 2021: $2,015 · 2022: $1,814 · 2023: $1,690 · 2024: $1,892 · 2025: $1,979.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,465 · Education: $96.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,465.04 |
| Education | $96.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,821.55 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $2,184.67 | 2019-2025 | Fasenra, Breztri, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,572.54 | 2019-2025 | Ofev, Jascayd |
| Grifols USA, LLC | $833.47 | 2019-2025 | Prolastin-C Liquid |
| Actelion Pharmaceuticals US, INC. | $687.19 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Insmed, INC. | $478.12 | 2019-2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $463.61 | 2019-2025 | |
| United Therapeutics Corporation | $448.93 | 2019-2025 | Tyvaso, Tyvaso |
| Amgen INC. | $329.20 | 2021-2025 | Tezspire |
| Baxter Healthcare | $237.38 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Regeneron Healthcare Solutions, INC. | $226.68 | 2019-2025 | Dupixent |
| Jazz Pharmaceuticals INC. | $220.54 | 2020-2024 | |
| Genentech USA, INC. | $213.32 | 2019-2023 | Xolair |
| Mylan Specialty L.P. | $203.46 | 2019-2024 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $170.15 | 2019-2025 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $136.16 | 2020-2025 | Glassia |
| Merck Sharp & Dohme LLC | $96.99 | 2023-2025 | Winrevair |
| Verona Pharma, INC. | $92.38 | 2025 | Ohtuvayre |
| Shire North American Group INC | $89.69 | 2019 | |
| Sanofi-Aventis U.S. LLC | $78.99 | 2024 | |
| Axsome Therapeutics, INC. | $76.99 | 2022-2025 | Sunosi |
| Mallinckrodt Enterprises LLC | $74.95 | 2019 | |
| Avadel Cns Pharmaceuticals, LLC | $63.37 | 2023-2024 | Lumryz |
| Mallinckrodt Hospital Products INC. | $61.97 | 2023 | Acthar |
| Philips North America LLC | $61.28 | 2020-2024 | (Ak6) Vest Therapy |
| Teva Pharmaceuticals USA, INC. | $61.15 | 2021-2022 | |
| Pfizer INC. | $60.55 | 2020-2024 | |
| Ani Pharmaceuticals, INC. | $58.28 | 2023-2024 | Purified Cortrophin Gel |
| 3b Medical, INC. | $52.72 | 2025 | Luna |
| Electromed, INC. | $45.64 | 2019-2022 | |
| Hikma Pharmaceuticals USA | $38.37 | 2023-2025 | Ryaltris |
| Circassia INC. | $36.76 | 2019 | |
| Vanda Pharmaceuticals INC. | $30.86 | 2023 | Hetlioz |
| Advanced Respiratory, INC | $24.94 | 2019-2020 | |
| Tempus Ai, INC | $24.75 | 2024 | |
| Inogen, INC. | $22.85 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Vifor Pharma, INC. | $20.61 | 2024 | Zemaira |
| Pulmonx Corporation | $18.91 | 2023 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Lilly USA, LLC | $18.52 | 2025 | Zepbound |
| Kaleo, INC. | $17.27 | 2020 | |
| Resmed Corp | $15.02 | 2024 | |
| Paratek Pharmaceuticals, INC. | $12.53 | 2020 | |
| Nabriva Therapeutics, Plc | $12.09 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Robins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.